Custom Truck One Source (CTOS) News & Sentiment

Custom Truck One Source, Inc. (NYSE:CTOS ) Q4 2024 Results Conference Call March 5, 2025 9:00 AM ET Company Participants Brian Perman - Vice President, Investor Relations Ryan McMonagle - CEO Christopher Eperjesy - CFO Conference Call Participants Justin Hauke - Robert W. Baird Tami Zakaria - JPMorgan Operator Hello, and thank you for standing by.

Custom Truck One Source, Inc. (CTOS) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.

KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, and other infrastructure-related end markets, today reported financial results for the fourth quarter and full year ended December 31, 2024. CTOS Fourth-Quarter and Full-Year Highlights Total quarterly revenue of $520.7 million, an increase of $73.5 million or 16.4%, compared to the third quarter of 2024 Full-year revenue of $1,802.3 mi.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Custom Truck One Source: My Downgrade To Buy Reflects State Of Demand

Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia SHELTON, Conn. , Nov. 18, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Christian F.

– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –

Custom Truck One Source, Inc. (CTOS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.04 per share a year ago.